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Abstract
Background: Individuals with high bone mass (HBM) have a greater odds of prevalent radiographic hip
osteoarthritis (OA), reflecting an association with bone-forming OA sub-phenotypes (e.g. osteophytosis, subchondral
sclerosis). As the role of bone mineral density (BMD) in hip OA progression is unclear, we aimed to determine if
individuals with HBM have increased incidence and/or progression of bone-forming OA sub-phenotypes.
Methods: We analysed an adult cohort with and without HBM (L1 and/or total hip BMD Z-score > + 3.2) with
pelvic radiographs collected at baseline and 8-year follow-up. Sub-phenotypes were graded using the OARSI atlas.
Superior/inferior acetabular/femoral osteophyte and medial/superior joint space narrowing (JSN) grades were
summed and Δosteophyte and ΔJSN derived. Pain and functional limitations were quantified using the WOMAC
questionnaire. Associations between HBM status and change in OA sub-phenotypes were determined using
multivariable linear/logistic regression, adjusting for age, sex, height, total body fat mass, follow-up time and
baseline sub-phenotype grade. Generalised estimating equations accounted for individual-level clustering.
Results: Of 136 individuals, 62% had HBM at baseline, 72% were female and mean (SD) age was 59 (10) years. HBM
was positively associated with both Δosteophytes and ΔJSN (adjusted mean grade differences between individuals
with and without HBM βosteophyte = 0.30 [0.01, 0.58], p = 0.019 and βJSN = 0.10 [0.01, 0.18], p = 0.019). Incident
subchondral sclerosis was rare. HBM individuals had higher WOMAC hip functional limitation scores (β = 8.3 [0.7,
15.98], p = 0.032).
Conclusions: HBM is associated with the worsening of hip osteophytes and JSN over an average of 8 years, as well
as increased hip pain and functional limitation.
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Introduction
Osteoarthritis (OA) of the hip is highly prevalent, affect-
ing approximately 1% of the worldwide population, sig-
nificantly contributing to global disability [1]. Currently,
no disease-modifying medications are available; therapy
consists of pain management until severity warrants a
total hip replacement (THR). Detection of risk factors
for hip OA progression offers an opportunity to identify
potential targets for the development of therapeutic
interventions.
Higher bone mineral density (BMD) has been associ-
ated with prevalent hip OA in several case-control [2, 3]
and population-based studies [4–7]. However, such ana-
lyses are complicated as BMD is often measured at the
hip and therefore it is hard to determine whether in-
creased BMD is a cause, or feature, of hip OA [4–6, 8].
In men with discordant hip OA, Arokoski et al. found
femoral neck (FN)-BMD to be 4% higher in the more se-
verely affected hip, reflecting increased FN volume (mea-
sured by MRI) [9]. This may reflect a process known as
buttressing, whereby osteophytes extend across the FN
to artefactually increase measured BMD [10]. However,
Chaganti et al. identified a relationship between total hip
(TH) cortical volumetric BMD (vBMD, measurement of
which it not artefactually increased by bone size) and
hip OA in 3886 men in the Study of Osteoporotic Frac-
tures in Men (MrOS) [5]. Moreover, lumbar spine (LS)-
BMD can be artefactually elevated by the presence of
spinal osteophytes, a feature of spinal OA [4–6]. How-
ever, Nevitt et al. found that the relationship between
LS-BMD and severe hip OA persisted despite adjust-
ment for spinal osteophytes [4]. Furthermore, they found
a relationship between calcaneal BMD and hip OA in
over 4000 women from the Study of Osteoporotic Frac-
tures (SOF), although of lower magnitude than seen for
TH-BMD [4].
More recently, in a unique population of individuals
with high bone mass (HBM), Hardcastle et al. reported
those with HBM to have an increased odds of hip OA,
reflecting a greater odds of osteophytosis but not joint
space narrowing (JSN) [10]. HBM in index cases was de-
fined as a TH or LS-BMD Z-score of at least + 3.2, with
a Z-score of at least + 1.2 at the other site, identifying a
generalised high BMD phenotype [11]. Genetic analysis
of HBM individuals suggests that the HBM phenotype is
at least in part determined by the polygenic inheritance
of multiple BMD-associated loci [12]; thus, the temporal
relationship is suggestive of a causal pathway between
generalised high BMD and prevalent hip OA.
Fewer longitudinal analyses have addressed the rela-
tionship between BMD and the incidence and/or pro-
gression of hip OA. In the Johnston County OA project
(JoCo) studying 928 older adults over median 6.5 years,
although BMD did not predict incident radiographic hip
OA, it was inversely associated with incident symptom-
atic radiographic hip OA [13]. Furthermore, Bergink
et al. identified an increased odds of both hip OA inci-
dence and progression in those in the highest quartile of
FN-BMD compared to the lowest quartile [14], whilst
Hochberg et al. identified a dose-response relationship
between both forearm and FN-BMD and the incidence
of hip OA in SOF [15].
We aimed to determine the role of high BMD in hip
OA by examining whether HBM individuals also have
an increased odds of hip OA incidence and/or progres-
sion, using 8-year follow-up data collected in this unique
cohort. We further aimed to determine the relationship
between HBM and clinical features of OA, namely pain
and functional limitations.
Methods
The high bone mass study
Participants were recruited as part of the UK-based
HBM study. Index cases were initially identified by
screening routine clinical National Health Service (NHS)
dual-energy X-ray absorptiometry (DXA) databases (254,
736 DXA scans from seven UK hospitals) for individuals
who had had T and/or Z-scores > + 4. All 1290 DXA im-
ages were inspected by trained clinicians to exclude
scans with artefactual elevations of DXA BMD (e.g. de-
generative disease, OA, surgical/malignant artefacts).
Full details of DXA database screening and participant
recruitment have been published [11]. Generalised HBM
was defined as a L1 or TH-BMD Z-score > + 3.2 with a
Z-score > + 1.2 at the other skeletal site. A + 3.2 thresh-
old was consistent with the only published precedent for
identifying HBM using DXA [16] and most appropriately
differentiated generalised HBM from artefact [11]. The
use of Z-score, rather than T-score, limited age bias [11].
Index cases passed on invitations to first-degree relatives
and spouses/partners who underwent the same assess-
ments. HBM in spouses was defined as per index cases.
In first-degree relatives, HBM was defined as summed
L1 plus TH Z-score > + 3.2, as this identified relatives
with BMD overlapping the index case BMD distribution
[11]. Participants who were aged < 18, pregnant or un-
able to give written informed consent were excluded.
Baseline recruitment of 363 adults (237 [65%] with
HBM) ran between 2005 and 2010 across seven NHS
centres (which participated in follow-up). Two hundred
seven (57%) were alive and contactable in 2016; 149
(72%) of whom completed a postal questionnaire and
attended for follow-up hip radiographs between 2017
and 2018 (Fig. 1).
Assessment of BMD
DXA scans were performed of the TH and LS at base-
line and, after 8 years follow-up, of the TH, LS and total
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body (TB) using standard protocols at each assessment
centre. All but five (97%) participants re-attended their
original centre, limiting measurement error due to dif-
ferential procedures. DXA scans were performed on
Hologic scanners in Bath, Bristol, Sheffield and St
George’s London and GE Lunar scanners in Cambridge
and Hull. Known differences in calibration exist between
Hologic and Lunar [17, 18]. We limited systematic bias
by converting TH and LS-BMD measures to standar-
dised BMD (sBMD) [18, 19]. All images were visually
inspected for positioning and metal artefacts (e.g. hip
prosthesis).
Assessment of radiographic OA
Standing anteroposterior (AP) pelvic X-rays were per-
formed at baseline and follow-up using standard proto-
cols at each centre. To limit observer bias, all
radiographs were pooled for analysis, with the reader
blinded to HBM status, demographics and timepoint.
Radiographs were graded for semi-quantitative OA sub-
Fig. 1 Flowchart detailing the baseline population through 8 years, to derive the follow-up population able to be studied
Table 1 Variables generated by Croft scoring and the OARSI atlas, with additional derived variables
Variable Grading Variable used in the analysis
Osteoarthritis (Croft
score)
0–5 Progressive OA: Croft score > 3 at baseline and an increase in score at follow-up
Incident OA: Croft score < 3 at baseline and > 3 at follow-up





inferior acetabular 0, 1




Abbreviations: OARSI Osteoarthritis Research Society International, JSN joint space narrowing, mJSW medial minimal joint space width
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phenotypes (osteophytes and JSN, graded 0–3) and sub-
chondral sclerosis (graded as present or absent) using
the OARSI atlas [20]. The presence or absence of sub-
chondral cysts was also evaluated. Overall OA was
graded using Croft scoring [21]. Generated and derived
progression variables are summarised in Table 1. Radio-
graphs, viewed in open source ImageJ software [22],
were inspected for poor image quality, rotation and/or
tilt. All readings were performed by one assessor (AH)
after focussed radiological training with a musculoskel-
etal radiologist (MW) and rheumatologist (SAH). A ran-
dom selection of 72 hips (20%) were regraded to
determine intra-rater reliability and graded by a second
reader (SAH) to determine inter-rater reliability.
Assessment of clinical OA
Hip pain and limitation of function were assessed by
postal questionnaire at 8-year follow-up. To limit
non-response bias, the questionnaire was resent if not
returned within 3 weeks. If still unreturned after a
further 2 weeks, a reminder telephone call was made.
The postal questionnaire included the short version
WOMAC function scale [23, 24], which limited par-
ticipant burden. The pain subscale (five questions re-
lating to pain walking on a flat surface, ascending/
descending stairs, at night, sitting or lying and stand-
ing upright) and function (seven questions relating to
difficulty ascending stairs, rising from sitting, walking
on flat, getting in/out of a car, putting on socks/
stockings, rising from bed and sitting) each had five
possible responses (none, mild, moderate, severe, ex-
treme) scored 0–4, respectively. Missing values for
pain or function questions were mean-imputed if a
participant was missing one question on the pain
scale and < 3 on the function scale. Average scores
were calculated for each subscale and scaled to give a
score ranging from 0 to 100, with 0 representing no
pain or functional limitation [25].
Covariate data
At baseline, structured interviews and clinical examin-
ation determined participant characteristics including
age and standing height. Total body fat mass (TBFM)
was assessed by TB DXA scan. Baseline menopausal sta-
tus, alcohol consumption and history of hormone re-
placement therapy (HRT) use and smoking were
determined by researcher-administered questionnaires.
Baseline physical activity levels were determined using
the International Physical Activity Questionnaire sent by
post [26–28]. Menopausal status, history of smoking and
highest educational status were determined by postal
questionnaire at follow-up.
Statistical analysis
Associations between HBM status and OA incidence
were determined by multivariable logistic regression. We
included all hips to increase sample size and thus statis-
tical power, using generalised estimating equations
(GEE), which account for correlation between hips from
the same individual and produce unbiased estimates in
analyses of clustered data [29]. This analysis was re-
stricted to hips with a Croft score < 3 at baseline.
Associations concerning change in osteophytes and
JSN (continuous variables) were determined by multivar-
iable GEE linear regression with robust standard errors
to account for any non-normal distributions in outcome
variables [30, 31]. Betas from analysis of continuous vari-
ables represent the difference in mean outcome between
those with and without HBM (e.g. a beta of 1 for change
in osteophyte score represents a 1-point greater increase
in osteophyte score in HBM individuals). Osteophyte
and/or JSN scores of 0 at baseline were included in ana-
lyses of change in osteophytes and JSN, optimising sam-
ple size. Analyses were initially performed unadjusted
(model 1) and then adjusted for age, sex and time be-
tween radiographs (and baseline sub-phenotype score
for continuous outcomes) (model 2). Our previous ana-
lyses found HBM to be associated with increased TBFM,
with evidence suggesting this is a consequence rather
than a cause of HBM [32]. Therefore, adiposity,
hypothesised to be on the causal pathway in these ana-
lyses, was adjusted for as TBFM in model 3 along with
height, to investigate a possible mediating effect of adi-
posity. Analyses were restricted to individuals with
complete data for model 3. Statistical analysis was per-
formed in Stata version 15 (Statacorp, USA) and R ver-
sion 3.5.1.
Sensitivity analyses
Joints with THR were excluded from the main analyses;
however, as THR may have been performed due to se-
vere OA, those with a baseline Croft score < 3 and THR
at follow-up were coded as incident OA cases, if they
had stated that their THR was performed due to ‘arth-
ritis’ (n = 4). Two individuals without OA at baseline,
who had a THR at follow-up due to fracture, were coded
as having no incident OA. A person-level analysis, using
the sum of the osteophyte and the sum of the JSN scores
for the two hips, used GEE to account for correlation
within families. Incident OA in person-level analyses
represents incident OA in either hip. A model adjusting
for metal artefacts on DXA images, analyses removing
individuals with DXA positioning errors potentially lead-
ing to under-measurement of TBFM (10 hips) and ana-
lyses removing individuals who visited a different study
site for follow-up (10 hips) were all performed. To check
that associations between HBM and change in OA sub-
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phenotypes were not explained by bone size, we per-
formed an additional analysis adjusting for the FN area
(measured at follow-up). Finally, to check if conclusions
were valid despite skewed continuous outcomes, all lin-
ear analyses were repeated using a Poisson model.
Results
Characteristics of the study population
Follow-up radiographic and covariate data were available
for 136 individuals, with 62% having HBM (index cases
or relatives with HBM). The proportion of individuals
with HBM did not differ between the populations with
and without follow-up data. Those with follow-up data
were younger, were less likely to have had hip OA at
baseline, to have ever smoked, to be postmenopausal,
but were more physically active (Supplementary Table 1).
Mean follow-up time for those with complete data was
8.2 (SD 1.0) years and did not differ between those with
and without HBM (Table 2). HBM cases were more
commonly female (85 vs 50%), with a trend towards a
higher proportion of postmenopausal women. HBM in-
dividuals had greater baseline BMD (mean TH-BMD
1.24 vs 0.98 g/cm2), BMI (29.8 vs 27.5 kg/m2) and TBFM
(33.0 vs 29.1 kg) than individuals without HBM (Table 2),
consistent with previous observations in this population
[11, 32]. Physical activity levels did not differ between
HBM individuals and those without HBM.
Repeatability of radiographic OA variables
Weighted intra-rater kappa statistics for the Croft score
and all osteophyte (except inferior acetabular) were > 0.7.
The intra-rater reliability kappa for inferior acetabular
osteophytes was 0.49, for medial JSN was 0.66 and for
superior JSN was 0.49. AH observed no acetabular scler-
osis or subchondral cysts. Intra-rater reliability for fem-
oral sclerosis was perfect. Inter-rater weighted kappas
for the Croft score and all osteophyte grades (except in-
ferior acetabular) were > 0.6, representing substantial
agreement [33]. The inter-rater kappa for inferior ace-
tabular osteophytes was 0.38, with kappas of 0.48 for
medial JSN and 0.39 for superior JSN. There was dis-
agreement on the one observed case of femoral sclerosis
and the one case of subchondral cysts, so these variables
were excluded from analyses.
Table 2 Characteristics of the study population, constituting individuals with and without HBM, who were followed up at 8 years
All, N = 136 HBM, N = 86 Relatives without HBM, N = 50 p value for difference
N (%)
Female gender 98 (72.1) 73 (84.9) 25 (50.0) < 0.001
Postmenopausalb 75 (76.5) 59 (80.8) 16 (64.0) 0.087
Menopause transition during the follow-up period 11 (11.2) 6 (8.2) 5 (20.0) 0.177
History of HRT usef 49 (50.0) 39 (53.4) 10 (40.0) 0.508
History of smokingf 66 (48.9) 42 (49.4) 24 (48.0) 0.874
Physical activity categoryb
Low 14 (10.7) 9 (11.0) 5 (10.2)
Medium 46 (35.1) 26 (31.7) 20 (40.8) 0.567
High 71 (54.2) 47 (57.3) 24 (49.0)
Education categoryf
Up to GCSE/O level 55 (42.0) 42 (50.0) 13 (27.7)
A level or equivalent 26 (19.9) 17 (20.2) 9 (19.2) 0.019
Degree or equivalent 50 (38.2) 25 (29.8) 25 (53.2)
Mean (SD)
Age, yearsb 59.2 (10.2) 60.2 (9.9) 57.5 (10.6) 0.136
Height, cmb 167.8 (9.6) 166.1 (8.4) 170.8 (10.8) 0.005
Weight, kgb 81.5 (17.0) 82.1 (16.0) 80.6 (18.7) 0.619
BMI (kg/m2)b 28.9 (5.5) 29.8 (5.6) 27.5 (5.1) 0.017
TBFM (kg)f 31.6 (10.6) 33.0 (10.9) 29.1 (9.5) 0.035
TH-BMD, g/cm2 b 1.143 (0.182) 1.242 (0.129) 0.976 (0.131) < 0.001
L1-BMD, g/cm2 b 1.255 (0.215) 1.377 (0.149) 1.049 (0.141) < 0.001
Follow-up time, years 8.2 (1.0) 8.2 (0.7) 8.2 (1.4) 0.817
Abbreviations: HBM high bone mass, HRT hormone replacement therapy, BMI body mass index, TBFM total body fat mass, TH-BMD total hip bone mineral density
bAssessed at baseline
fAssessed as follow-up
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Table 3 Prevalence of radiographic and clinical sub-phenotypes of OA in the study population, stratified by HBM status
All hips HBM hips Non-HBM hips
Total N N (%) with sub-phenotype Total N N (%) with sub-phenotype Total N N (%) with sub-phenotype
OA (Croft > 3)
Baseline 285 22 (7.7) 179 13 (7.3) 106 9 (8.5)
Follow-up 275 33 (12.0) 173 24 (13.9) 102 9 (8.8)
Incident 257 18 (7.0) 162 15 (9.3) 95 3 (3.2)
Progressive 18 5 (27.8) 11 2 (18.2) 7 3 (42.9)
Hip replacement (identified on radiograph)
Baseline 290 5 (1.7) 184 5 (2.7) 106 0
Follow-up 290 15 (5.2) 184 11 (6.0) 106 4 (3.8)
Incident 285 10 (3.5) 179 6 (3.4) 106 4 (3.8)
Osteophyte score
Baseline 285 179 106
0 203 (71.2) 126 (70.4) 77 (72.6)
1–4 75 (26.3) 50 (27.9) 25 (23.6)
> 5 7 (2.5) 5 (2.8) 4 (3.8)
Follow-up 275 173 102
0 161 (58.6) 94 (54.3) 67 (65.7)
1–4 105 (38.2) 73 (42.2) 32 (31.4)
> 5 9 (3.3) 6 (3.5) 3 (2.9)
Delta 275 173 102
< 1 201 (73.1) 121 (69.9) 80 (78.4)
1 48 (17.5) 32 (18.5) 16 (15.7)
> 1 26 (9.5) 20 (11.6) 6 (5.9)
JSN score
Baseline 285 179 106
0 253 (88.8) 160 (89.4) 93 (87.7)
1–2 27 (9.5) 16 (8.9) 11 (10.4)
> 3 5 (1.8) 3 (1.7) 2 (1.9)
Follow-up 275 173 102
0 241 (87.6) 149 (86.1) 92 (90.2)
1–2 28 (10.2) 20 (11.6) 8 (7.8)
> 3 6 (2.2) 4 (2.3) 2 (2.0)
Delta 275 173 102
< 1 261 (94.9) 161 (93.1) 100 (98.0)
1 12 (4.4) 10 (5.8) 2 (2.0)
> 1 2 (0.7) 2 (1.2) 0 (0.0)
All individuals HBM individuals Relatives without HBM
Total N Median (IQR) Total N Median (IQR) Total N Median (IQR)
WOMAC at follow-up
Pain 145 0 (0, 25) 92 10 (0, 35) 53 0 (0, 15)
Function 145 3.6 (0, 25) 92 10.7 (0, 30.4) 53 0 (0, 14.3)
Total N N (%) Total N N (%) Total N N (%)
Hip replacement (self-reported) 145 16 (11.0) 92 13 (14.1) 53 3 (5.7)
Abbreviations: HBM high bone mass, OA osteoarthritis, JSN joint space narrowing, WOMAC Western Ontario and McMaster Universities
Osteoarthritis Index
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HBM and the incidence and progression of overall hip OA
Radiographic hip OA was observed in 7.7% of all 290
hips at baseline and 12.0% at follow-up (Table 3). Of the
257 OA-free hips at baseline, 7.0% developed OA. There
was no clear evidence that HBM was associated with an
increased risk of overall incident OA measured by Croft
score, before (model 1, OR = 2.54 [95%CI 0.66, 9.71],
Fig. 2) or after adjustment for age, sex and follow-up
time (model 2, 1.65 [0.41, 6.70]). Due to the low baseline
prevalence of overall OA defined as Croft score ≥ 3 (i.e.
the presence of osteophytes and JSN), we were unable to
analyse OA progression. Using Croft score > 1 to define
OA at baseline, 82 hips had potential to progress, of
which 16 had a higher Croft score at follow-up than
baseline (12 with HBM). However, no clear association
between HBM and overall OA progression was observed
(model 3, OR 4.14 [0.81, 21.3], Fig. 2). When combining
incident and progressive OA to generate a variable for
any incident or progressive hip OA, HBM was still not
clearly associated with the overall change in hip OA se-
verity (model 3, OR 1.72 [0.58, 5.11]).
Combined incidence and progression of radiographic hip
OA sub-phenotypes
Of the total population, 28.8% hips had at least one
osteophyte at baseline, rising to 41.5% at follow-up
(Table 3). JSN was much less prevalent at baseline and
follow-up (11.3% and 12.4%, respectively). In unadjusted
analyses, we found evidence that individuals with HBM
experienced greater changes in both osteophyte and JSN
scores than individuals without HBM (βosteophyte = 0.30
[0.05, 0.54], p = 0.019 and βJSN = 0.09 [0.01, 0.16], p =
0.019, β reflects the difference in the mean change in
osteophyte/JSN score between those with and without
HBM). These associations persisted after adjustment for
age, sex, follow-up time, baseline score, height and
TBFM (model 3) (Fig. 2).
HBM and clinical features of hip OA
HBM was associated with 12-point [95% CI 5, 18] higher
WOMAC pain scores and 13-point [7, 19] higher func-
tion scores in unadjusted analyses. Adjustment for age,
sex, height and TBFM attenuated these relationships by
Fig. 2 Associations between HBM and incident and progressive OA and change in OA sub-phenotypes. Points for continuous outcomes
represent the difference in mean outcome between individuals with and without HBM (for example, a beta of 1 for change in osteophyte score
would represent a 1-point greater increase in summed osteophyte score, which is the equivalent of the appearance of one additional osteophyte
over 8 years or the increase in the size of an osteophyte already present). Points for binary outcomes represent the odds ratio for individuals with
HBM compared to their relatives with normal BMD. Model 1: unadjusted; model 2: adjusted for age, sex and follow-up time (plus baseline score
for continuous outcomes); model 3: adjusted for age, sex, follow-up time, height and TBFM (plus baseline score for continuous outcomes).
Nincident OA = 248; Ncontinuous outcomes = 263. Abbreviation: JSN joint space narrowing
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approximately one-third to one-half (βpain = 6.4 [− 1.4,
14.2], p = 0.105 and βfunction = 8.3 [0.7, 15.8], p = 0.032, β
represents the difference in mean WOMAC score be-
tween those with and without HBM). Further adjust-
ment for osteophyte or JSN score at follow-up did not
appear to explain these relationships (Fig. 3). There was
some weak evidence supporting an increased odds of
self-reported hip replacement in individuals with HBM
who completed the follow-up questionnaire, compared
to those without HBM (age, sex, height and TBFM-
adjusted OR = 4.27 [0.94, 19.5], p = 0.061, N = 148).
Sensitivity analyses
Including six individuals with an incident THR and a
Croft score < 3 at baseline in the analysis of incident OA
did not alter conclusions drawn. Neither did removing
10 hips from individuals who visited a different study
site for follow-up radiographs, removing hips from indi-
viduals with DXA positioning errors, nor additional ad-
justment for TB DXA artefact. Conclusions were
unchanged when performing a person-level analysis ac-
counting for within-family clustering, although CIs were
wider due to the reduced sample size (Supplementary
Figure 1). Additional adjustment for the FN area (as a
measure of bone size) marginally attenuated effect esti-
mates (βosteophyte = 0.26 [0.01, 0.52] to 0.21[− 0.02, 0.44]
and βJSN = 0.08 [0.01, 0.16] to 0.07 [4.74 × 10
−3, 0.13]).
Conclusions were unchanged when using a Poisson
model, although the association between HBM and
change in JSN score was stronger than the association
with change in osteophyte score; however, it should be
noted that these analyses may be biased by the need to
recode negative values as zero.
Discussion
We have found evidence for increased osteophyte devel-
opment (i.e. incidence and/or progression) and JSN at the
hip, over an average of 8 years in individuals with HBM,
compared to their relatives without HBM. Radiographic
JSN is thought to indirectly reflect cartilage loss [34]. Fur-
thermore, individuals with HBM have more hip pain and
limitation of function in their daily activities, which adds
further evidence for increased OA severity in this popula-
tion. Low statistical power limited our ability to draw
strong conclusions about the relationship between HBM
and overall incident OA, based on the Croft score.
Few studies have determined the association between
BMD and hip OA incidence or progression. Bergink
et al. observed a relationship between FN-BMD and
both hip OA incidence and progression in the Rotter-
dam study population [14]. We have extended these
findings by determining the relationship between high
BMD and the incidence and/or progression of individual
radiographic sub-phenotypes. Barbour et al. identified
weak evidence for worsening osteophytes with increasing
BMD in JoCo, but no evidence for a relationship with
Fig. 3 Associations between HBM status and WOMAC pain and function sub-scale scores. Points represent the mean difference in WOMAC
scores between individuals with HBM and relatives/spouses without HBM. Person-level analysis, accounting for clustering in families. Follow-up
osteophyte and JSN score is the highest of the two hips. Model 1: unadjusted; model 2: adjusted for age and sex; model 3: adjusted for age, sex,
height and total body fat mass; model 4: model 3 plus osteophyte severity at follow-up, model 5: model 3 plus JSN severity at follow-up. N = 127
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JSN progression [13], which is inconsistent with our ob-
served (albeit weak) relationship between HBM and
change in JSN score. Hochberg et al. identified a dose-
response relationship between BMD and subsequent in-
cidence of OA in SOF [15]. However, this relationship
was no longer present when defining incidence based on
JSN alone. In our analyses, whilst we did not observe
strong evidence for an association between HBM and in-
cident hip OA, possibly due to low numbers, the direc-
tion of effect was consistent with previous findings.
Our observed relationship between HBM and hip pain
is consistent with studies of population-based cohorts,
which have identified an increased BMD in those report-
ing hip pain [4]. The severity of OA sub-phenotypes did
not appear to explain the relationship between HBM
and hip pain or functional limitations, suggesting that
HBM individuals have an increased risk of clinical OA
independent of radiographic severity. The WOMAC
questionnaire measures pain over the past 48 h, which
may explain why radiographic OA severity did not ex-
plain current pain, as pain could increase during stages
of rapid OA progression not captured by radiographs
[35]. An analysis of the Framingham and OA Initiative
populations found that fewer than 25% of individuals
with radiographic hip OA reported hip pain, and fewer
than 20% reporting hip pain had radiographic hip OA
[36]. It is possible that increased pain and functional
limitation in the HBM population could reflect other
conditions of the hip, such as bursitis [37] or features of
a mild skeletal dysplasia, or inflammation not detected
on the radiograph.
Increased TBFM in the HBM population [32] did not
appear to explain the relationship between HBM and
change in radiographic OA sub-phenotypes. Adjustment
for the FN area, as a measure of bone size, only ex-
plained a small proportion of the relationship. Unfortu-
nately, we do not have measures of FN width, a reported
risk factor for hip OA progression [38]. It is plausible
that HBM individuals would have greater FN width due
to greater bone mass meaning measures of FN area may
not equate to FN width in this population. Another fac-
tor which may mediate the relationship between HBM
and development of hip OA sub-phenotypes is differ-
ences in hip shape. HBM individuals more commonly
have features of cam-type deformity (i.e. larger femoral
head size and reduced sphericity) compared to their rel-
atives without HBM [39]. Evidence suggests that cam-
type deformities are a risk factor for end-stage hip OA
and hence potentially for hip OA progression [40, 41].
Although HBM is likely to be caused by the polygenic
inheritance of multiple BMD loci [12], or the monogenic
inheritance of rare variants [42], indicating that HBM
precedes OA development, we cannot rule out the possi-
bility that biological pleiotropy, rather than a causal
effect, explains our results. We have previously identified
an increased prevalence of pelvic enthesophytes in the
HBM population, leading to the hypothesis that HBM
individuals may have a genetic predisposition to form
extra bone [43]. We observed a stronger effect size for
the relationship between HBM and change in hip osteo-
phyte score, than we did for that between HBM and
change in hip JSN score, which further suggests a ‘bone-
forming’ phenotype in this population. Further evidence
for pleiotropy was provided by Hackinger et al. who
found weak evidence for a genetic correlation between
hip OA and LS-BMD, but not hip OA and FN-BMD
[44]. By performing a cross-phenotype meta-analysis be-
tween overall OA and LS-BMD, the authors identified
novel loci in the SMAD3 gene [44]. SMAD3 is part of
the transforming growth factor β (TGFβ) signalling
pathway, regulating osteoblast differentiation and thus
bone formation. The first discovered hip OA locus,
growth differentiation factor-5 (GDF5), is a ligand for
this pathway [45], suggesting that this pathway contrib-
utes to both BMD and hip OA.
Strengths and limitations
The HBM study constitutes the largest population of in-
dividuals with extreme, unexplained, generalised HBM
[11]. We analysed change in OA sub-phenotypes separ-
ately, which allowed us to detect the stronger relation-
ship with osteophyte development compared to change
in JSN. We analysed change in osteophytes and JSN as
continuous measures, increasing statistical power to de-
tect associations and reducing the possibility of a ceiling
effect by increasing the range of possible values from 0
to 6 for JSN and 0 to 10 for osteophytes and eliminating
the possibility of selection bias in a case-only analysis.
The method of identifying individuals from NHS DXA
databases ascertained a predominantly female and older
population such that a relatively large proportion were
unable to be followed up after 8 years, due to death or
poor health. Hence, there was a lower baseline preva-
lence of radiographic hip OA in the population able to
be followed up, meaning we had limited power to assess
hip OA incidence and progression based on the overall
Croft score. The baseline cross-sectional study was pow-
ered to determine if the odds of OA differed between
HBM individuals and their relatives with an expected re-
cruitment of 200 cases and 200 controls [10]. However,
loss-to-follow-up over 8 years reduced our sample size
and a retrospective power calculation for the analyses
presented here showed that we had approximately 65%
power to detect the change in osteophyte and JSN scores
reported here and lower power to detect a difference in
proportion of incident hip OA between HBM individuals
and their non-HBM relatives. Radiographs and DXA
scans were performed using standard protocols at each
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centre but were not standardised across centres. However,
as 97% of individuals re-attended the same centre for
follow-up, this is unlikely to affect our measures for
change in radiographic features. Furthermore, measuring
change in sub-phenotype variables did not separate hip
OA sub-phenotype progression from incidence since these
results had to be pooled to optimise sample size. As base-
line and follow-up radiographs were not read as pairs, we
did observe a few negative scores for change in osteo-
phytes (8%) and change in JSN (1.5%), which were in-
cluded in analyses, because removing these values as
‘measurement error’ would have biased results as there
was likely to have been the same proportion of measure-
ment error overinflating change, for which we would not
have been able to account (hence the reasoning for not
basing conclusions on the Poisson analysis). Radiographic
grading of OA sub-phenotypes is subjective, which we
limited using an established atlas [20], although our intra-
rater and inter-rater reliability were low for a few vari-
ables, attenuating the conclusions we can draw from this
analysis. As the reader was blinded to timepoint, it is un-
likely that radiographic features were systematically
under-graded at baseline and over-graded at follow-up,
meaning measurement error is unlikely to explain our re-
sults. WOMAC scores were only collected at follow-up,
and therefore, we cannot draw conclusions about the rela-
tionship between HBM and symptomatic OA progression.
Finally, as HBM individuals represent a rare and extreme
tail of the BMD distribution, findings may not be general-
isable to the wider population.
Conclusions
We have found evidence for associations between HBM
and worsening of radiographic sub-phenotypes of hip OA
over 8 years. We further provide evidence for greater
symptoms of OA in HBM individuals. These associations
are independent of the elevated fat mass observed in
HBM individuals. Further genetic analyses are planned to
determine the BMI-independent causal role of BMD in
hip OA progression and to identify the underlying bio-
logical pathways explaining these associations.
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